Summit4CI Speaker Series

Summit4CI Speaker Series

Summit for Cancer Immunotherapy: Speaker Series
Hosted by BioCanRx, Canada's Immunotherapy Network

The in-person Summit for Cancer Immunotherapy has been postponed due to the current pandemic. But, in the meantime, BioCanRx is pleased to offer a series of interesting and interactive virtual talks featuring our funded Network Investigators from across the country. Each speaker session will include a plain language overview and wrap up, with an opportunity for questions. Best of all, it's free to attend.

View Previous Sessions

Session Nine: Register now!

Harnessing the power of tumor infiltrating lymphocytes (TIL) by cell selection for adoptive transfer immunotherapy
Date: Monday, June 28, 2021 | 1:30 - 3:00pm ET

A small number of anti-tumor immune cells, called T cells, can naturally infiltrate tumors in most patients, but fail to control cancer growth. Current antibody-based immunotherapy designed to boost these anti-tumor T cells are only efficacious in a minority of patients. Another way to therapeutically harness anti-tumor T cells consists in producing them in large numbers outside the body and transfusing them to patients. In this project, we propose to make a T cell transfusion product highly enriched in tumor-reactive T cells using patients' own tumor as source material.

This is achieved by sorting T cells from surgically removed tumor. Cell sorting is based on the expression by T cells of a cell surface marker called PD-1, which acts as a "tag" for tumor-reactivity. We have optimized the parameters of a sophisticated cell sorter and the cell culture conditions to expand the sorted T cells to large numbers for infusion into patients. The main goal of this project is to test the feasibility, the safety, and the potential efficacy of this T cell immunotherapy in 24 patients with metastatic melanoma resistant to standard treatment. To guide the design of subsequent trials, we will characterize the biologic features of the starting tumors and the T cell products for their association with treatment efficacy and side effects. Enrolled patients will be offered to participate in a patient-led support group to help them understand and communicate to others what to expect from anti-tumor T cell transfusion immunotherapy.


Simon Turcotte
Sandy Pelletier

Who should attend?

Scientific and health care community including researchers, clinicians and HQP along with patients and caregivers. Note: There will be a plain language overview before the session begins and an opportunity to ask questions after the discussion.

You can find details about our Scientific Programming Committee here

Register now!

You can read more about this research project here:

Questions? Contact [email protected]